{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:44Z","timestamp":1790014304034,"version":"4.0.1"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pathological complete response (pCR) of neoadjuvant chemotherapy (NACT) is the most important predictor of successful treatment in locally advanced breast cancer and is associated with survival outcomes. The aim of our study is to investigate a validated nomogram that predicted MammaPrint\u00ae to assess the response rate in luminal type breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively included patients from Asan Medical Center, Seoul, South Korea who were diagnosed with luminal type breast cancer and received NACT and underwent breast cancer surgery from August 2008 to December 2021. We used a nomogram previously published by colleagues at our center, using a cutoff score of 183. The primary outcome of this study was to investigate the use of nomogram adopted from a 70-gene MammaPrint for prediction of pCR following NACT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 1,574 patients were collected. The nomogram using MammaPrint predicted pCR (odds ratio 2.092, 95% confidence interval 1.507\u20132.905; p\u2009&lt;\u20090.001). Based on multivariate logistic regression analysis, estrogen receptor status, progesterone receptor status, clinical tumor stage, clinical node stage, and Ki67 index were independent predictive factors of pCR in the primary cohort. The area under the curve of the validated nomogram was 0.64 (95% confidence interval, 0.60\u20130.67), indicating the nomogram predicted pCR in the neoadjuvant setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides evidence that the adopted nomogram using the MammaPrint risk assessment based on clinicopathological pre-NACT factors can be utilized in luminal type breast cancer to aid in treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0356871","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:38:46Z","timestamp":1790012326000},"page":"e0356871","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a nomogram predicting pathologic complete response to neoadjuvant chemotherapy in luminal type breast cancer patients using MammaPrint\u00ae and clinicopathological factor"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2497-4096","authenticated-orcid":true,"given":"Sarah","family":"Al safi","sequence":"first","affiliation":[{"name":"Al Adan Hospital","place":["Hadiya, Ministry of Health, Kuwait"],"department":["Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Kyung","family":"Yoo","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Yong","family":"Chung","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Seok","family":"Ko","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Won","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Son","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-6937","authenticated-orcid":true,"given":"Sae Byul","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Ulsan College of Medicine, Asan Medical Center","place":["Seoul, Republic of Korea"],"department":["Division of Breast Surgery, Department of Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"3","key":"pone.0356871.ref001","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4048\/jbc.2019.22.e35","article-title":"Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype- Breast Cancer","volume":"22","author":"HS Kim","year":"2019","journal-title":"J Breast Cancer"},{"issue":"15","key":"pone.0356871.ref002","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"G von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0356871.ref003","first-page":"103","article-title":"Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer","volume":"10","author":"A Pennisi","year":"2016","journal-title":"Breast Cancer"},{"key":"pone.0356871.ref004","doi-asserted-by":"crossref","first-page":"103280","DOI":"10.1016\/j.critrevonc.2021.103280","article-title":"Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: When, why and what?","volume":"160","author":"R Torrisi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"pone.0356871.ref005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.amjsurg.2020.11.053","article-title":"Neoadjuvant chemotherapy for luminal a breast cancer: Factors predictive of histopathologic response and oncologic outcome","volume":"222","author":"PM Collins","year":"2021","journal-title":"Am J Surg"},{"key":"pone.0356871.ref006","doi-asserted-by":"crossref","first-page":"17588359221138657","DOI":"10.1177\/17588359221138657","article-title":"Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy","volume":"15","author":"G Garufi","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"pone.0356871.ref007","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1200\/JCO.2023.41.16_suppl.521","article-title":"MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST","volume":"41","author":"PD Beitsch","year":"2023","journal-title":"JCO"},{"key":"pone.0356871.ref008","unstructured":"Early and locally advanced breast cancer: diagnosis and management. NICE; 2018."},{"key":"pone.0356871.ref009","doi-asserted-by":"crossref","first-page":"8284814","DOI":"10.1155\/2022\/8284814","article-title":"Luminal A breast cancer: how feasible is omitting axillary dissection without neoadjuvant therapy","volume":"2022","author":"C Y\u00fcksel","year":"2022","journal-title":"Breast J"},{"key":"pone.0356871.ref010","doi-asserted-by":"crossref","first-page":"878255","DOI":"10.3389\/fsurg.2022.878255","article-title":"Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study","volume":"9","author":"Y Li","year":"2022","journal-title":"Front Surg"},{"issue":"1","key":"pone.0356871.ref011","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1186\/s12885-020-07621-7","article-title":"Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT)","volume":"20","author":"S Pu","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"pone.0356871.ref012","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2007.14.3222","article-title":"Clinical application of the 70-gene profile: the MINDACT trial","volume":"26","author":"F Cardoso","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0356871.ref013","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1245\/s10434-016-5600-x","article-title":"Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping","volume":"24","author":"P Whitworth","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"pone.0356871.ref014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0356871.ref015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12672-022-00604-z","article-title":"Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer","volume":"13","author":"YS Hwang","year":"2022","journal-title":"Discov Oncol"},{"issue":"1","key":"pone.0356871.ref016","doi-asserted-by":"crossref","first-page":"43","DOI":"10.14449\/jbd.2020.8.1.43","article-title":"Predictive Factors for Non-Response to Neoadjuvant Chemotherapy for Breast Cancer","volume":"8","author":"M Jin","year":"2020","journal-title":"J Breast Dis"},{"issue":"3","key":"pone.0356871.ref017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy","volume":"170","author":"W Haque","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"pone.0356871.ref018","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00404-021-06018-6","article-title":"Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy","volume":"304","author":"C M\u00fcller","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"pone.0356871.ref019","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","author":"JA Sarano","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0356871.ref020","author":"J McKelley","journal-title":"Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens. San Antonio Breast Cancer Symporsium December 8-11 2020. Poster ID # PS6-19"},{"key":"pone.0356871.ref021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2022.03.003","article-title":"Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions","volume":"167","author":"E G\u00f6ker","year":"2022","journal-title":"Eur J Cancer"},{"key":"pone.0356871.ref022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BD-150199","article-title":"The impact of Oncotype DX\u00ae recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer","volume":"36","author":"A Soran","year":"2016","journal-title":"Breast Dis"},{"issue":"2","key":"pone.0356871.ref023","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1245\/s10434-018-07107-8","article-title":"Oncotype DX\u00ae Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy","volume":"26","author":"AM Pease","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"pone.0356871.ref024","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10549-011-1488-0","article-title":"Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics","volume":"131","author":"EH Lips","year":"2012","journal-title":"Breast Cancer Res Treat"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:38:52Z","timestamp":1790012332000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356871"}},"subtitle":[],"editor":[{"given":"UDAYAN","family":"BHATTACHARYA","sequence":"first","affiliation":[{"name":"Weill Cornell University","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0356871","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}